<?xml version="1.0" encoding="UTF-8"?>
<p>HTLV-1 positive samples were originated from a cross-sectional study conducted among 2019 repeat blood donors at the Maputo Central Hospital blood bank in Maputo city between August and December 2006, where the prevalence of the infection is 0.9% 
 <xref rid="pntd.0001038-Gudo1" ref-type="bibr">[18]</xref>. HTLV/HIV positive samples were originated from a cross-sectional survey conducted among HIV-positive adult individuals naive to Highly Active Antiretroviral Therapy (HAART) attending an HIV Outpatient Clinic in Maputo, between March and June of 2006, with prevalence of HTLV/HIV co-infection of 4.5%. Demographic information is on Gudo et al. 
 <xref rid="pntd.0001038-Gudo1" ref-type="bibr">[18]</xref>. All twenty-five specimens, 14 from blood donors and 11 from HTLV/HIV co-infected individuals, were positive by HTLV enzyme immunoassays [Murex HTLV I+II, (Abbott/Murex, Wiesbaden, Germany) and Vironostika HTLVI/II (bioMÃ©rieux bv, Boxtel, Netherlands], and confirmed by HTLV BLOT 2.4 (Genelabs Diagnostics, Singapura). The HIV positive individuals were screened by two rapid tests: Determine HIV 1/2 test (Abbott Laboratories, Tokyo, Japan) and Unigold HIV test (Trinity Biotech, Ireland).
</p>
